<DOC>
	<DOC>NCT00722371</DOC>
	<brief_summary>A study to evaluate the efficacy and safety of sitagliptin and pioglitazone co-administration in comparison with sitagliptin and pioglitazone monotherapy in patients with type 2 diabetes.</brief_summary>
	<brief_title>MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Patient is highly unlikely to conceive Patient meets one of the 3 categories is naïve to all antihyperglycemic agent (AHA) therapies, or is nonnaïve based upon the patient's current diet, medical regimen and screening A1c patient is currently not on AHA with a screening A1c &gt;=7.5 % and =&lt;11.0 % patient is currently on either metformin pr sulfonylurea monotherapy with a screening A1c &gt;=7.0 % and =&lt;9.0 % Exclusion Criteria Patient has a history of type 1 diabetes mellitus or history of ketoacidosis or has C=peptide value of =&lt;0.8 ng/mL Patient has previously been treated with insulin, thiazolidinedione (TZD) (rosiglitazone or pioglitazone), any Dipeptidyl peptidase4 (DPP4) inhibitor (sitagliptin, vildagliptin, or alogliptin), exenatide or has previously been in a clinical study with any DPP4 inhibitor or incretin mimetic Patient is on a weight loss program and is not in the maintenance phase or has started a weight loss medication (e.g. orlistat or sibutramine) within the prior 8 weeks Patient has undergone surgery within the prior 30 days or has major surgery planned during the study Patient has a medical history of active liver disease including chronic active hepatitis B or C or symptomatic gallbladder disease including primary biliary cirrhosis Patient has received treatment with an investigational product within 12 weeks prior to Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>